Simpler Grants.gov #RFA-CA-25-035

NCI Limited Competition for Biospecimen Banking Services for Cancer Clinical Trials

The National Cancer Institute (NCI) is forecasting a limited competition funding opportunity to support the continued operation of two major biospecimen banks for cancer clinical trials. - Government Buyer: - National Institutes of Health (NIH), National Cancer Institute (NCI) - Scope of Work: - Operation and maintenance of the National Clinical Trials Network (NCTN) Biospecimen Banks - Responsibilities include collection, processing, storage, and distribution of clinically annotated human biospecimens from NCI-funded clinical trials - Operation and maintenance of the Early-Phase and Experimental Clinical Trials (EET) Biobank - Focuses on biospecimens from early-phase and experimental clinical trials involving investigational new drugs - Products/Services Requested: - Biobanking services (no specific products or part numbers requested) - Unique/Notable Requirements: - Eligibility is limited to current recipients of NCTN and EET biobank awards under previous RFAs - Up to six awards are expected - Total program funding is $19,100,000 - This is a forecast notice; applications are not yet being solicited - No specific OEMs or vendors are named; the focus is on institutional biobanking services - Place of Performance: - National Institutes of Health (NIH)

Description

The National Cancer Institute (NCI) is soliciting applications to support continuation of two biospecimen banking resources: the National Clinical Trials Network (NCTN) Biospecimen Banks and the Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank). These resources support the collection, processing, storage, and distribution of clinically annotated human biospecimens from NCI-funded clinical trials focused on cancer treatment, prevention, and control. The NCTN Biobanks support biobanking operations for large multi-site clinical trials, while the EET Biobank focuses on early-phase and experimental clinical trials involving investigational new drugs. This limited competition NOFO aims to maintain these national resources to enable translational cancer research and biomarker development.

View original listing